Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Biotech drugs blaze a trail

Despite a total research budget just one-quarter that of the largest pharmaceutical firms, since 2003, public biotech companies have shepherded more new molecular entities (NMEs) to approval than big pharma. This success is reflected by increased in-licensing by the pharma sector. At the same time, the US Food and Drug Administration is now seeing more New Drug Applications and Investigational New Drug Submissions, many of these compounds (three in every ten) originating from groups outside the United States.

Big pharma defined as 15 largest pharmaceutical companies by market cap. Source: Ernst & Young
Source: Food and Drug Administration
Source: Ernst & Young
&Includes biologics. Source: Food and Drug Administration
Based on an analysis of the top ten pharma companies. Source: Tufts Center for the Study of Drug Development
&Includes biologics. Source: Food and Drug Administration
Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lawrence, S. Biotech drugs blaze a trail. Nat Biotechnol 24, 736 (2006). https://doi.org/10.1038/nbt0706-736

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0706-736

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing